TALIS BIOMEDICAL CORP - COM NEW (TLIS)

CUSIP: 87424L207

Q3 2023 13F Holders as of 30 Sep 2023

Type / Class
Equity / COM NEW
Total 13F shares
740,595
Share change
-6,894,240
Total reported value
$4,272,687
Price per share
$5.77
Number of holders
18
Value change
-$39,727,415
Number of buys
17
Number of sells
2

Quarterly Holders Quick Answers

What is CUSIP 87424L207?
CUSIP 87424L207 identifies TLIS - TALIS BIOMEDICAL CORP - COM NEW in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of TALIS BIOMEDICAL CORP - COM NEW (TLIS) as of Q3 2023

As of 30 Sep 2023, TALIS BIOMEDICAL CORP - COM NEW (TLIS) was held by 18 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 740,595 shares. The largest 10 holders included BAKER BROS. ADVISORS LP, GREENLIGHT CAPITAL INC, VANGUARD GROUP INC, PRELUDE CAPITAL MANAGEMENT, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, GEODE CAPITAL MANAGEMENT, LLC, CITIGROUP INC, BlackRock Inc., MORGAN STANLEY, and Tower Research Capital LLC (TRC). This page lists 18 institutional shareholders reporting positions in this security for the Q3 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.